ID   MTRR_HUMAN              Reviewed;         725 AA.
AC   Q9UBK8; O60471; Q32MA9; Q7Z4M8;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   10-MAY-2017, entry version 169.
DE   RecName: Full=Methionine synthase reductase;
DE            Short=MSR;
DE            EC=1.16.1.8;
GN   Name=MTRR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS A; B AND C), AND
RP   VARIANT LEU-202.
RX   PubMed=10564814; DOI=10.1016/S0378-1119(99)00431-X;
RA   Leclerc D., Odievre M.-H., Wu Q., Wilson A., Huizenga J., Rozen R.,
RA   Scherer S.W., Gravel R.A.;
RT   "Molecular cloning, expression and physical mapping of the human
RT   methionine synthase reductase gene.";
RL   Gene 240:75-88(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS B AND C), VARIANT LEU-202, AND
RP   VARIANT HMAE LEU-603 DEL.
RX   PubMed=9501215; DOI=10.1073/pnas.95.6.3059;
RA   Leclerc D., Wilson A., Dumas R., Gafuik C., Song D., Watkins D.,
RA   Heng H.H.Q., Rommens J.M., Scherer S.W., Rosenblatt D.S., Gravel R.A.;
RT   "Cloning and mapping of a cDNA for methionine synthase reductase, a
RT   flavoprotein defective in patients with homocystinuria.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:3059-3064(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS A AND B).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   SUBCELLULAR LOCATION (ISOFORM A).
RX   PubMed=18221906; DOI=10.1016/j.ymgme.2007.11.019;
RA   Froese D.S., Wu X., Zhang J., Dumas R., Schoel W.M., Amrein M.,
RA   Gravel R.A.;
RT   "Restricted role for methionine synthase reductase defined by
RT   subcellular localization.";
RL   Mol. Genet. Metab. 94:68-77(2008).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-198, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-198 AND SER-216, VARIANT
RP   [LARGE SCALE ANALYSIS] LEU-202, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-216, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 192-725 IN COMPLEX WITH FAD
RP   AND NADP, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, CATALYTIC ACTIVITY,
RP   AND FUNCTION.
RX   PubMed=17892308; DOI=10.1021/bi701209p;
RA   Wolthers K.R., Lou X., Toogood H.S., Leys D., Scrutton N.S.;
RT   "Mechanism of coenzyme binding to human methionine synthase reductase
RT   revealed through the crystal structure of the FNR-like module and
RT   isothermal titration calorimetry.";
RL   Biochemistry 46:11833-11844(2007).
RN   [11]
RP   VARIANTS HMAE VAL-81 DEL; MET-83; THR-156; ARG-432; ARG-514 AND
RP   ARG-581, AND VARIANT VAL-360.
RX   PubMed=10484769; DOI=10.1093/hmg/8.11.2009;
RA   Wilson A., Leclerc D., Rosenblatt D.S., Gravel R.A.;
RT   "Molecular basis for methionine synthase reductase deficiency in
RT   patients belonging to the cblE complementation group of disorders in
RT   folate/cobalamin metabolism.";
RL   Hum. Mol. Genet. 8:2009-2016(1999).
RN   [12]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO NTDFS, AND VARIANT MET-49.
RX   PubMed=10444342; DOI=10.1006/mgme.1999.2879;
RA   Wilson A., Platt R., Wu Q., Leclerc D., Christensen B., Yang H.,
RA   Gravel R.A., Rozen R.;
RT   "A common variant in methionine synthase reductase combined with low
RT   cobalamin (vitamin B12) increases risk for spina bifida.";
RL   Mol. Genet. Metab. 67:317-323(1999).
RN   [13]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO NTDFS, AND VARIANT MET-49.
RX   PubMed=12375236; DOI=10.1086/344209;
RA   Doolin M.-T., Barbaux S., McDonnell M., Hoess K., Whitehead A.S.,
RA   Mitchell L.E.;
RT   "Maternal genetic effects, exerted by genes involved in homocysteine
RT   remethylation, influence the risk of spina bifida.";
RL   Am. J. Hum. Genet. 71:1222-1226(2002).
RN   [14]
RP   VARIANTS MET-49; LEU-202 AND ARG-377.
RX   PubMed=15979034; DOI=10.1016/j.ymgme.2005.02.003;
RA   O'Leary V.B., Mills J.L., Pangilinan F., Kirke P.N., Cox C.,
RA   Conley M., Weiler A., Peng K., Shane B., Scott J.M.,
RA   Parle-McDermott A., Molloy A.M., Brody L.C.;
RT   "Analysis of methionine synthase reductase polymorphisms for neural
RT   tube defects risk association.";
RL   Mol. Genet. Metab. 85:220-227(2005).
CC   -!- FUNCTION: Involved in the reductive regeneration of cob(I)alamin
CC       (vitamin B12) cofactor required for the maintenance of methionine
CC       synthase in a functional state. Necessary for utilization of
CC       methylgroups from the folate cycle, thereby affecting
CC       transgenerational epigenetic inheritance. Folate pathway donates
CC       methyl groups necessary for cellular methylation and affects
CC       different pathways such as DNA methylation, possibly explaining
CC       the transgenerational epigenetic inheritance effects.
CC       {ECO:0000269|PubMed:17892308}.
CC   -!- CATALYTIC ACTIVITY: 2 [methionine synthase]-methylcob(I)alamin + 2
CC       S-adenosylhomocysteine + NADP(+) = 2 [methionine synthase]-
CC       cob(II)alamin + NADPH + 2 S-adenosyl-L-methionine.
CC       {ECO:0000269|PubMed:17892308}.
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000269|PubMed:17892308};
CC   -!- COFACTOR:
CC       Name=FMN; Xref=ChEBI:CHEBI:58210;
CC         Evidence={ECO:0000269|PubMed:17892308};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=2.89 uM for NADPH {ECO:0000269|PubMed:17892308};
CC         KM=3540 uM for NADH {ECO:0000269|PubMed:17892308};
CC   -!- INTERACTION:
CC       Q53SE7:FLJ13057; NbExp=3; IntAct=EBI-10319161, EBI-10172181;
CC   -!- SUBCELLULAR LOCATION: Isoform B: Cytoplasm.
CC   -!- SUBCELLULAR LOCATION: Isoform C: Cytoplasm.
CC   -!- SUBCELLULAR LOCATION: Isoform A: Cytoplasm
CC       {ECO:0000269|PubMed:18221906}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=A;
CC         IsoId=Q9UBK8-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=Q9UBK8-2; Sequence=VSP_003910;
CC       Name=C;
CC         IsoId=Q9UBK8-3; Sequence=VSP_003910, VSP_003911, VSP_003912;
CC   -!- TISSUE SPECIFICITY: Found in all tissues tested, particularly
CC       abundant in skeletal muscle.
CC   -!- DISEASE: Homocystinuria-megaloblastic anemia, cblE complementation
CC       type (HMAE) [MIM:236270]: An autosomal recessive inborn error of
CC       metabolism resulting from defects in the cobalamin-dependent
CC       pathway that converts homocysteine to methionine. It causes
CC       delayed psychomotor development, megaloblastic anemia,
CC       homocystinuria, and hypomethioninemia. Cells from patients with
CC       HMAE fail to incorporate methyltetrahydrofolate into methionine in
CC       whole cells, but cell extracts show normal methionine synthase
CC       activity in the presence of a reducing agent.
CC       {ECO:0000269|PubMed:10484769, ECO:0000269|PubMed:9501215}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Neural tube defects, folate-sensitive (NTDFS)
CC       [MIM:601634]: The most common NTDs are open spina bifida
CC       (myelomeningocele) and anencephaly. {ECO:0000269|PubMed:10444342,
CC       ECO:0000269|PubMed:12375236}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=The hidden things -
CC       Issue 166 of December 2014;
CC       URL="http://web.expasy.org/spotlight/back_issues/166/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF121213; AAF17303.1; -; Genomic_DNA.
DR   EMBL; AF121202; AAF17303.1; JOINED; Genomic_DNA.
DR   EMBL; AF121203; AAF17303.1; JOINED; Genomic_DNA.
DR   EMBL; AF121204; AAF17303.1; JOINED; Genomic_DNA.
DR   EMBL; AF121205; AAF17303.1; JOINED; Genomic_DNA.
DR   EMBL; AF121206; AAF17303.1; JOINED; Genomic_DNA.
DR   EMBL; AF121207; AAF17303.1; JOINED; Genomic_DNA.
DR   EMBL; AF121208; AAF17303.1; JOINED; Genomic_DNA.
DR   EMBL; AF121209; AAF17303.1; JOINED; Genomic_DNA.
DR   EMBL; AF121210; AAF17303.1; JOINED; Genomic_DNA.
DR   EMBL; AF121211; AAF17303.1; JOINED; Genomic_DNA.
DR   EMBL; AF121212; AAF17303.1; JOINED; Genomic_DNA.
DR   EMBL; AF121214; AAF16876.1; -; mRNA.
DR   EMBL; AF121213; AAF17304.1; -; Genomic_DNA.
DR   EMBL; AF121202; AAF17304.1; JOINED; Genomic_DNA.
DR   EMBL; AF121203; AAF17304.1; JOINED; Genomic_DNA.
DR   EMBL; AF121204; AAF17304.1; JOINED; Genomic_DNA.
DR   EMBL; AF121205; AAF17304.1; JOINED; Genomic_DNA.
DR   EMBL; AF121206; AAF17304.1; JOINED; Genomic_DNA.
DR   EMBL; AF121207; AAF17304.1; JOINED; Genomic_DNA.
DR   EMBL; AF121208; AAF17304.1; JOINED; Genomic_DNA.
DR   EMBL; AF121209; AAF17304.1; JOINED; Genomic_DNA.
DR   EMBL; AF121210; AAF17304.1; JOINED; Genomic_DNA.
DR   EMBL; AF121211; AAF17304.1; JOINED; Genomic_DNA.
DR   EMBL; AF121212; AAF17304.1; JOINED; Genomic_DNA.
DR   EMBL; AF025794; AAC39667.1; -; mRNA.
DR   EMBL; AC010346; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC025174; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC054816; AAH54816.2; -; mRNA.
DR   EMBL; BC109216; AAI09217.1; -; mRNA.
DR   CCDS; CCDS3874.1; -. [Q9UBK8-1]
DR   CCDS; CCDS47190.1; -. [Q9UBK8-2]
DR   RefSeq; NP_002445.2; NM_002454.2. [Q9UBK8-2]
DR   RefSeq; NP_076915.2; NM_024010.2. [Q9UBK8-1]
DR   UniGene; Hs.481551; -.
DR   PDB; 2QTL; X-ray; 1.90 A; A=192-725.
DR   PDB; 2QTZ; X-ray; 1.90 A; A=192-725.
DR   PDBsum; 2QTL; -.
DR   PDBsum; 2QTZ; -.
DR   ProteinModelPortal; Q9UBK8; -.
DR   SMR; Q9UBK8; -.
DR   BioGrid; 110645; 14.
DR   DIP; DIP-61183N; -.
DR   IntAct; Q9UBK8; 8.
DR   STRING; 9606.ENSP00000264668; -.
DR   DrugBank; DB00115; Cyanocobalamin.
DR   DrugBank; DB00200; Hydroxocobalamin.
DR   DrugBank; DB00134; L-Methionine.
DR   iPTMnet; Q9UBK8; -.
DR   PhosphoSitePlus; Q9UBK8; -.
DR   SwissPalm; Q9UBK8; -.
DR   BioMuta; MTRR; -.
DR   DMDM; 296439300; -.
DR   EPD; Q9UBK8; -.
DR   MaxQB; Q9UBK8; -.
DR   PaxDb; Q9UBK8; -.
DR   PeptideAtlas; Q9UBK8; -.
DR   PRIDE; Q9UBK8; -.
DR   Ensembl; ENST00000264668; ENSP00000264668; ENSG00000124275. [Q9UBK8-1]
DR   Ensembl; ENST00000440940; ENSP00000402510; ENSG00000124275. [Q9UBK8-2]
DR   Ensembl; ENST00000510279; ENSP00000427200; ENSG00000124275. [Q9UBK8-3]
DR   Ensembl; ENST00000514369; ENSP00000426132; ENSG00000124275. [Q9UBK8-3]
DR   GeneID; 4552; -.
DR   KEGG; hsa:4552; -.
DR   UCSC; uc003jed.4; human. [Q9UBK8-1]
DR   CTD; 4552; -.
DR   DisGeNET; 4552; -.
DR   GeneCards; MTRR; -.
DR   GeneReviews; MTRR; -.
DR   H-InvDB; HIX0031952; -.
DR   HGNC; HGNC:7473; MTRR.
DR   HPA; HPA038113; -.
DR   MalaCards; MTRR; -.
DR   MIM; 236270; phenotype.
DR   MIM; 601634; phenotype.
DR   MIM; 602568; gene.
DR   neXtProt; NX_Q9UBK8; -.
DR   OpenTargets; ENSG00000124275; -.
DR   Orphanet; 2169; Methylcobalamin deficiency type cblE.
DR   PharmGKB; PA31277; -.
DR   eggNOG; KOG1158; Eukaryota.
DR   eggNOG; COG0369; LUCA.
DR   GeneTree; ENSGT00840000129757; -.
DR   HOGENOM; HOG000007485; -.
DR   HOVERGEN; HBG108376; -.
DR   InParanoid; Q9UBK8; -.
DR   KO; K00597; -.
DR   OMA; FSVICPN; -.
DR   OrthoDB; EOG091G045Q; -.
DR   PhylomeDB; Q9UBK8; -.
DR   TreeFam; TF105716; -.
DR   BioCyc; MetaCyc:HS04756-MONOMER; -.
DR   BRENDA; 1.16.1.8; 2681.
DR   Reactome; R-HSA-156581; Methylation.
DR   Reactome; R-HSA-1614635; Sulfur amino acid metabolism.
DR   Reactome; R-HSA-196741; Cobalamin (Cbl, vitamin B12) transport and metabolism.
DR   Reactome; R-HSA-3359467; Defective MTRR causes methylmalonic aciduria and homocystinuria type cblE.
DR   Reactome; R-HSA-3359469; Defective MTR causes methylmalonic aciduria and homocystinuria type cblG.
DR   SABIO-RK; Q9UBK8; -.
DR   EvolutionaryTrace; Q9UBK8; -.
DR   GeneWiki; MTRR_(gene); -.
DR   GenomeRNAi; 4552; -.
DR   PRO; PR:Q9UBK8; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000124275; -.
DR   CleanEx; HS_MTRR; -.
DR   ExpressionAtlas; Q9UBK8; baseline and differential.
DR   Genevisible; Q9UBK8; HS.
DR   GO; GO:0005829; C:cytosol; TAS:UniProtKB.
DR   GO; GO:0030586; F:[methionine synthase] reductase activity; IDA:BHF-UCL.
DR   GO; GO:0050444; F:aquacobalamin reductase (NADPH) activity; IDA:CACAO.
DR   GO; GO:0071949; F:FAD binding; IDA:BHF-UCL.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IDA:UniProtKB.
DR   GO; GO:0010181; F:FMN binding; IDA:BHF-UCL.
DR   GO; GO:0050661; F:NADP binding; TAS:UniProtKB.
DR   GO; GO:0070402; F:NADPH binding; IDA:BHF-UCL.
DR   GO; GO:0003958; F:NADPH-hemoprotein reductase activity; IDA:BHF-UCL.
DR   GO; GO:0016723; F:oxidoreductase activity, oxidizing metal ions, NAD or NADP as acceptor; IDA:UniProtKB.
DR   GO; GO:0009235; P:cobalamin metabolic process; TAS:Reactome.
DR   GO; GO:0006306; P:DNA methylation; ISS:UniProtKB.
DR   GO; GO:0046655; P:folic acid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0043418; P:homocysteine catabolic process; IDA:BHF-UCL.
DR   GO; GO:0009086; P:methionine biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0006555; P:methionine metabolic process; TAS:UniProtKB.
DR   GO; GO:0032259; P:methylation; TAS:Reactome.
DR   GO; GO:1904042; P:negative regulation of cystathionine beta-synthase activity; IDA:BHF-UCL.
DR   GO; GO:0055114; P:oxidation-reduction process; TAS:UniProtKB.
DR   GO; GO:0033353; P:S-adenosylmethionine cycle; ISS:BHF-UCL.
DR   GO; GO:0000096; P:sulfur amino acid metabolic process; TAS:Reactome.
DR   Gene3D; 3.40.50.360; -; 1.
DR   InterPro; IPR003097; FAD-binding_1.
DR   InterPro; IPR017927; Fd_Rdtase_FAD-bd.
DR   InterPro; IPR001094; Flavdoxin-like.
DR   InterPro; IPR008254; Flavodoxin/NO_synth.
DR   InterPro; IPR001709; Flavoprot_Pyr_Nucl_cyt_Rdtase.
DR   InterPro; IPR029039; Flavoprotein-like_dom.
DR   InterPro; IPR001433; OxRdtase_FAD/NAD-bd.
DR   InterPro; IPR017938; Riboflavin_synthase-like_b-brl.
DR   Pfam; PF00667; FAD_binding_1; 1.
DR   Pfam; PF00258; Flavodoxin_1; 1.
DR   Pfam; PF00175; NAD_binding_1; 1.
DR   PRINTS; PR00369; FLAVODOXIN.
DR   PRINTS; PR00371; FPNCR.
DR   SUPFAM; SSF52218; SSF52218; 1.
DR   SUPFAM; SSF63380; SSF63380; 1.
DR   PROSITE; PS51384; FAD_FR; 1.
DR   PROSITE; PS50902; FLAVODOXIN_LIKE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Amino-acid biosynthesis;
KW   Complete proteome; Cytoplasm; Disease mutation; FAD; Flavoprotein;
KW   FMN; Methionine biosynthesis; NADP; Oxidoreductase; Phosphoprotein;
KW   Polymorphism; Reference proteome; S-adenosyl-L-methionine.
FT   CHAIN         1    725       Methionine synthase reductase.
FT                                /FTId=PRO_0000021785.
FT   DOMAIN       32    174       Flavodoxin-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00088}.
FT   DOMAIN      298    560       FAD-binding FR-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00716}.
FT   NP_BIND     120    151       FMN. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00088}.
FT   NP_BIND     478    481       FAD. {ECO:0000269|PubMed:17892308}.
FT   NP_BIND     514    517       FAD. {ECO:0000269|PubMed:17892308}.
FT   NP_BIND     637    638       NADP. {ECO:0000269|PubMed:17892308}.
FT   NP_BIND     651    653       NADP. {ECO:0000269|PubMed:17892308}.
FT   REGION      193    274       Hinge.
FT   BINDING     318    318       NADP. {ECO:0000269|PubMed:17892308}.
FT   BINDING     686    686       NADP. {ECO:0000269|PubMed:17892308}.
FT   BINDING     724    724       FAD. {ECO:0000269|PubMed:17892308}.
FT   MOD_RES     198    198       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     216    216       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ       1     27       Missing (in isoform B and isoform C).
FT                                {ECO:0000303|PubMed:10564814,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9501215}.
FT                                /FTId=VSP_003910.
FT   VAR_SEQ      71     85       YDLKTETAPLVVVVS -> VSVIQNTPTFAMGGR (in
FT                                isoform C). {ECO:0000303|PubMed:10564814,
FT                                ECO:0000303|PubMed:9501215}.
FT                                /FTId=VSP_003911.
FT   VAR_SEQ      86    725       Missing (in isoform C).
FT                                {ECO:0000303|PubMed:10564814,
FT                                ECO:0000303|PubMed:9501215}.
FT                                /FTId=VSP_003912.
FT   VARIANT      49     49       I -> M (polymorphism; may increase risk
FT                                for spina bifida; dbSNP:rs1801394).
FT                                {ECO:0000269|PubMed:10444342,
FT                                ECO:0000269|PubMed:12375236,
FT                                ECO:0000269|PubMed:15979034}.
FT                                /FTId=VAR_012836.
FT   VARIANT      81     81       Missing (in HMAE).
FT                                {ECO:0000269|PubMed:10484769}.
FT                                /FTId=VAR_012837.
FT   VARIANT      83     83       V -> M (in HMAE; dbSNP:rs761061866).
FT                                {ECO:0000269|PubMed:10484769}.
FT                                /FTId=VAR_012838.
FT   VARIANT     156    156       A -> T (in HMAE).
FT                                {ECO:0000269|PubMed:10484769}.
FT                                /FTId=VAR_012839.
FT   VARIANT     202    202       S -> L (in dbSNP:rs1532268).
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:10564814,
FT                                ECO:0000269|PubMed:15979034,
FT                                ECO:0000269|PubMed:9501215}.
FT                                /FTId=VAR_034595.
FT   VARIANT     284    284       S -> T (in dbSNP:rs2303080).
FT                                /FTId=VAR_034596.
FT   VARIANT     360    360       L -> V (in dbSNP:rs10064631).
FT                                {ECO:0000269|PubMed:10484769}.
FT                                /FTId=VAR_012840.
FT   VARIANT     377    377       K -> R (in dbSNP:rs162036).
FT                                {ECO:0000269|PubMed:15979034}.
FT                                /FTId=VAR_034597.
FT   VARIANT     432    432       C -> R (in HMAE).
FT                                {ECO:0000269|PubMed:10484769}.
FT                                /FTId=VAR_012841.
FT   VARIANT     442    442       R -> C (in dbSNP:rs2287780).
FT                                /FTId=VAR_034598.
FT   VARIANT     477    477       P -> R (in dbSNP:rs16879334).
FT                                /FTId=VAR_034599.
FT   VARIANT     514    514       G -> R (in HMAE; dbSNP:rs137853061).
FT                                {ECO:0000269|PubMed:10484769}.
FT                                /FTId=VAR_012842.
FT   VARIANT     542    542       A -> V (in dbSNP:rs16879355).
FT                                /FTId=VAR_056947.
FT   VARIANT     581    581       G -> R (in HMAE).
FT                                {ECO:0000269|PubMed:10484769}.
FT                                /FTId=VAR_015731.
FT   VARIANT     603    603       Missing (in HMAE).
FT                                {ECO:0000269|PubMed:9501215}.
FT                                /FTId=VAR_012843.
FT   VARIANT     622    622       H -> Y (in dbSNP:rs10380).
FT                                /FTId=VAR_014944.
FT   HELIX       262    264       {ECO:0000244|PDB:2QTL}.
FT   STRAND      277    282       {ECO:0000244|PDB:2QTL}.
FT   STRAND      301    310       {ECO:0000244|PDB:2QTL}.
FT   STRAND      320    326       {ECO:0000244|PDB:2QTL}.
FT   STRAND      339    343       {ECO:0000244|PDB:2QTL}.
FT   HELIX       348    357       {ECO:0000244|PDB:2QTL}.
FT   HELIX       361    363       {ECO:0000244|PDB:2QTL}.
FT   STRAND      366    372       {ECO:0000244|PDB:2QTL}.
FT   HELIX       393    399       {ECO:0000244|PDB:2QTL}.
FT   HELIX       409    416       {ECO:0000244|PDB:2QTL}.
FT   HELIX       422    432       {ECO:0000244|PDB:2QTL}.
FT   HELIX       437    443       {ECO:0000244|PDB:2QTL}.
FT   TURN        444    448       {ECO:0000244|PDB:2QTL}.
FT   HELIX       451    457       {ECO:0000244|PDB:2QTL}.
FT   HELIX       465    471       {ECO:0000244|PDB:2QTL}.
FT   STRAND      478    481       {ECO:0000244|PDB:2QTL}.
FT   TURN        486    488       {ECO:0000244|PDB:2QTL}.
FT   STRAND      492    498       {ECO:0000244|PDB:2QTL}.
FT   STRAND      501    503       {ECO:0000244|PDB:2QTL}.
FT   STRAND      510    513       {ECO:0000244|PDB:2QTL}.
FT   HELIX       515    523       {ECO:0000244|PDB:2QTL}.
FT   TURN        524    527       {ECO:0000244|PDB:2QTL}.
FT   STRAND      546    551       {ECO:0000244|PDB:2QTL}.
FT   STRAND      567    570       {ECO:0000244|PDB:2QTL}.
FT   HELIX       573    576       {ECO:0000244|PDB:2QTL}.
FT   HELIX       577    592       {ECO:0000244|PDB:2QTL}.
FT   STRAND      601    608       {ECO:0000244|PDB:2QTL}.
FT   TURN        610    612       {ECO:0000244|PDB:2QTL}.
FT   HELIX       617    625       {ECO:0000244|PDB:2QTL}.
FT   STRAND      631    639       {ECO:0000244|PDB:2QTL}.
FT   HELIX       652    658       {ECO:0000244|PDB:2QTL}.
FT   HELIX       660    669       {ECO:0000244|PDB:2QTL}.
FT   STRAND      673    679       {ECO:0000244|PDB:2QTL}.
FT   HELIX       681    699       {ECO:0000244|PDB:2QTL}.
FT   HELIX       703    715       {ECO:0000244|PDB:2QTL}.
FT   STRAND      718    723       {ECO:0000244|PDB:2QTL}.
SQ   SEQUENCE   725 AA;  80410 MW;  C3EF82DAC388BAF1 CRC64;
     MGAASVRAGA RLVEVALCSF TVTCLEVMRR FLLLYATQQG QAKAIAEEIC EQAVVHGFSA
     DLHCISESDK YDLKTETAPL VVVVSTTGTG DPPDTARKFV KEIQNQTLPV DFFAHLRYGL
     LGLGDSEYTY FCNGGKIIDK RLQELGARHF YDTGHADDCV GLELVVEPWI AGLWPALRKH
     FRSSRGQEEI SGALPVASPA SSRTDLVKSE LLHIESQVEL LRFDDSGRKD SEVLKQNAVN
     SNQSNVVIED FESSLTRSVP PLSQASLNIP GLPPEYLQVH LQESLGQEES QVSVTSADPV
     FQVPISKAVQ LTTNDAIKTT LLVELDISNT DFSYQPGDAF SVICPNSDSE VQSLLQRLQL
     EDKREHCVLL KIKADTKKKG ATLPQHIPAG CSLQFIFTWC LEIRAIPKKA FLRALVDYTS
     DSAEKRRLQE LCSKQGAADY SRFVRDACAC LLDLLLAFPS CQPPLSLLLE HLPKLQPRPY
     SCASSSLFHP GKLHFVFNIV EFLSTATTEV LRKGVCTGWL ALLVASVLQP NIHASHEDSG
     KALAPKISIS PRTTNSFHLP DDPSIPIIMV GPGTGIAPFI GFLQHREKLQ EQHPDGNFGA
     MWLFFGCRHK DRDYLFRKEL RHFLKHGILT HLKVSFSRDA PVGEEEAPAK YVQDNIQLHG
     QQVARILLQE NGHIYVCGDA KNMAKDVHDA LVQIISKEVG VEKLEAMKTL ATLKEEKRYL
     QDIWS
//
